Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. Announce Manufacturing and Research Partnership Partnership focused on developing innovative manufacturing, product development, and customer support as the

Pharmaceuticals Corporation and Sharps Technology, Inc. Announce

Manufacturing and Research Partnership

focused on developing innovative manufacturing, product development, and

customer support as the Company prepares to launch its proprietary

InjectEZ syringe product

COLUMBIA, S.C. & NEW YORK - Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. (the "Company") (NASDAQ:

"STSS" and "STSSW"), an innovative medical device and drug delivery company offering patented, best-in-class

syringe products, announced today a new partnership focused on developing and sharing best practices in innovative manufacturing, product

development, customer support, and quality as Nephron prepares to launch the Company's InjectEZ component of expansion.

Technology is a medical device and pharmaceutical packaging company specializing in developing and manufacturing innovative drug delivery

systems. Nephron Pharmaceuticals is known across the country to health systems and hospitals as a leader in the production of affordable

generic inhalation solutions and suspension products, as well as pre-filled sterile syringes, luer-lock vials, IV bottles, and IV bags.

InjectEZ is part of the Nephron investment of hundreds of millions of dollars over the last two years to increase manufacturing capacity

in its Lexington County, S.C. facilities.

are excited to kick off a partnership with Sharps Technology, as our InjectEZ expansion project opens, for a variety of innovative initiatives,

including research and development," said Lou Kennedy, Nephron's CEO. "Just as the InjectEZ syringe manufacturing facility

is poised to play a critical role in assisting those with whom we work on tackling emerging public health crises, Sharps Technology also

offers key solutions to healthcare challenges. We look forward to working with them."

product lines have historically focused on low waste and ultra-low waste syringe technologies, which allow up to 40% more injections

per vial of therapy while incorporating multiple passive safety features. These features protect front-line healthcare workers from life-threatening

needle stick injuries and protect the public from needle re-use. The partnership with Nephron opens opportunities for Sharps to expand

its portfolio and make an impact on the specialized pre-fillable syringe and drug delivery systems market.

Technology has identified a unique opportunity to collaborate with a leader in the industry like Nephron," said Robert Hayes, CEO

of Sharps Technology. "Through my previous industry experience supporting and working with most of the leading healthcare and pharmaceutical

companies in the world, it was easy for me to evaluate Nephron Pharmaceuticals as a potential partner. They truly are a leader in all

areas of business and an example of best in class for the industry. I appreciate and look forward to the opportunity to work with Bill

and Lou Kennedy and their leadership team to make this collaboration a success for both companies."

Technology brings extensive expertise in syringes to Nephron, including experience with specialized pre-filled syringe systems and ready-to-use

processing. The pre-filled syringe lines will utilize the highly automated equipment and controlled environments established by Nephron.

These premium pre-filled polymer offerings will be made from the highest quality raw materials, on the most innovative technology, and

will be compliant with the USP standards required in the United States as well as the EP and JP international standards.

products that will be developed and commercialized provide solutions to support the current Nephron fill/finish strategies as well as

their pipeline of new drug applications and sets forward a strategy to support branded pharma and advanced therapies, including ophthalmic

and biologic applications.

Technology will also be partnering with Nephron Pharmaceuticals in the development of a Pharmaceuticals Services Program designed to

support healthcare customers that need innovative solutions and products to support their business. The development of this program will

help create new fill/finish project opportunities for Nephron that will utilize innovative packaging solutions developed by Sharps Technology.

These new customer projects will fuel the growth of both companies, and the opportunity to create new technologies to support the healthcare

industry will be transformative for Nephron and Sharps as they navigate a bright future working together.

Sharps Technology, Inc.

Technology, Inc. is a medical device company addressing global issues while engineering a safer future for healthcare providers and people

everywhere through compassionate innovation. Sharps Provensa is the Company's premier line of smart safety syringes that

eliminate accidental needlestick injuries, prevent improper needle reuse, and reduce wasted medicine and vaccines-while retaining

the intuitive simplicity of traditional syringes. Please visit SharpsTechnology.com to learn more.

press release contains "forward-looking statements" Forward-looking statements reflect our current view about future events.

When used in this press release, the words "anticipate," "believe," "estimate," "expect,"

"future," "intend," "plan," or the negative of these terms and similar expressions, as they relate

to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained

in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking

statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because

forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances

that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They

are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying

on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the

forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect

our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other

providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability

to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual

results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that

could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot

guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking

statements in order to reflect any event or circumstance that may arise after the date of this release.

Holdsworth, Managing Director